TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Slides:

Advertisements

Similar presentations

Reference Anker SD. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. The FAIR-HF Trial Ferric.

Advertisements

THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.

חזק בהגנה לבבית Valsartan in Heart Failure

analysis from the SHIFT study

SOLVD (Studies of Left Ventricular Dysfunction)

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support SURVIVE-WSURVIVE-W Presented at The American Heart Association Scientific.

Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

ACCP Cardiology PRN Journal Club

Thrombectomy in Acute Stroke

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

The use of Intravenous Iron Therapy in Iron Deficient Patients with Heart Failure with Reduced Ejection Fraction: Decrease Hospitalizations and Improve.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

Nat. Rev. Cardiol. doi: /nrcardio

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Biomarker-Guided HF Therapy: Is It Cost-Effective?

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

Nat. Rev. Cardiol. doi: /nrcardio

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

Modified Rankin score 0-2

EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

End point Fenoldopam, n (%) Dopamine, n (%) p

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Anaerobic threshold responder analysis

(p for noninferiority < 0.001)

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Post-Heart Failure Mortality

Romain Gallet et al. BTS 2016;1:14-28

Baseline Clinical Characteristics

The FAIR-HF Trial Reference

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

MATRIX: Radial vs. Femoral

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48 hours (n = 129) versus placebo (n = 128). Results (p = 0.32) % responders at 24 hours (moderate or marked improvement and no need for rescue therapy or death): 16% with tolvaptan versus 20% with placebo (p = 0.32) Mean fluid loss at 24 hours: 2182 cc with tolvaptan versus 1541 cc with placebo (p = 0.006) % 20 16 Conclusions Among patients hospitalized with acute heart failure and treated with standard intravenous diuretic therapy, the addition of tolvaptan versus placebo did not improve dyspnea symptoms Tolvaptan Placebo Felker GM, et al. J Am Coll Cardiol 2016;Sep 18:[Epub]